Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 8/20 | 0.72 |
| ▸ | THRB | P10828 | 8/20 | 0.72 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.65 |
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347446 | 0.86 | FFAR4 (0.67) | THRATHRBFFAR1FFAR4PTGER1 | |
| SCHEMBL4887009 | 0.85 | THRA (0.75) | THRATHRBFFAR1FFAR4ESR1 | |
| SCHEMBL4892311 | 0.84 | THRA (1.00) | THRATHRBFFAR1FFAR4ESR1 | |
| SCHEMBL4896380 | 0.84 | THRB (0.73) | THRATHRBFFAR1FFAR4ESR1 | |
| SCHEMBL6725149 | 0.82 | THRA (0.47) | THRATHRBFFAR1FFAR4PTGER1 | |
| SCHEMBL4898411 | 0.81 | THRA (0.70) | THRATHRBFFAR1FFAR4ESR1 | |
| SCHEMBL4900710 | 0.81 | THRA (0.69) | THRATHRBFFAR1FFAR4ESR1 | |
| SCHEMBL4899365 | 0.80 | THRA (0.67) | THRATHRBFFAR1FFAR4ESR1 | |
| SCHEMBL1745638 | 0.79 | FFAR1 (1.00) | FFAR1FFAR4PTGER1PTGER4PTGER3 | |
| SCHEMBL4890896 | 0.79 | THRA (0.66) | THRATHRBFFAR1FFAR4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRA 559/4885THRB 792/4885FFAR1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.